Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
2 Dec, 22
10 Oct, 22
Key session presented at the European Respiratory Society (ERS) International Congress 2022, 3rd-6th Sept. 2022, Barcelona.
A recent study concluded that early initiation of SGLT2i in people with preserved eGFR may provide kidney protection benefits. SGLT2i reduced risk of renal disease progression by 27% to 57% and HF outcomes by 13% to 32% for all eGFR categories, reported the study. Greatest risk reduction for HF outcomes was reported for lower eGFR values (eGFR <30 ml/min/1.73m2).
Findings from a recent study suggests higher risk of CVD, IHD, and mortality from all-cause in T2DM patients with disrupted CRAR. Decreased day-to-day consistency, robustness, or high fragmentation in circadian rest-activity rhythm may indicate higher risks of CVD and mortality in patients with T2DM, reported the study.
- Significant LV dysfunction persists even after about 3 months of recovery from acute COVID-19
- Nonhospitalized patients had a better CAT score (p=0.04), higher change in max pulse rate (p = 0.03), and higher FEV1 (p=0.002) and TAPSE (p=0.02)
- The hospitalized patients had significantly worse LVGLS (–17.15 vs –13.11) (p=0.0001)
- Autoantibody positivity was seen in confirmed PTB subjects without any coexisting autoimmune disease
- PTB patients showed a high prevalence of anti-elastase (96.6%) and a low prevalence of ANA, anti-PR3 antibodies (7.8%), anti-MPO and anti-lactoferrin antibodies were not detected
- ANCA positivity should be interpreted with caution in TB endemic areas.
Featured

6 Jul, 22

28 Mar, 22

16 Aug, 21